2024-03-28T09:38:24Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00019251
2022-12-15T03:50:12Z
453:456
471:537:538:1148
The Effect of New Antiplatelet Treatment on Saphenous Vein Graft in Coronary Bypass Surgery : The 2nd Report : Surgical Aspect and Early Results
新しい抗血小板療法による冠状動脈バイパス術後の閉塞防止の研究 : 第二報 : 外科治療と早期成績
新しい抗血小板療法による冠状動脈バイパス術後の閉塞防止の研究 : 第二報 : 外科治療と早期成績
林, 純一
119936
小熊, 文昭
119937
中沢, 聡
119938
江口, 昭治
119939
丸山, 行夫
119940
山添, 優
119941
和泉, 徹
119942
柴田, 昭
119943
服部, 晃
119944
aspirin
ticlopidine
saphenous vein graft
graft patency
アスピリン
チクロピジン
大不在静脈グラフト
グラフト開存率
In order to clarify the benefit of treatment using ticlopidine with low-dose aspirin on saphenous vein graft patency after aorto-coronary bypass, a randomized study was performed on 135 patients who were operated between January 1987 and March 1991 at Niigata University Hospital or Niigata Kobari Hospital. Among them, 38 patients were excluded from the study because they didn't meet the protocol requirements. Subjects were divided into antiplatelet therapy (AT) group (n=58) and control group (n=39). Saphenous vein graft patency was evaluated by coronary angiography 1 month after the operation. Although the overall graft patency rate was 86.5% in the AT group and 81.4% in the control group (N.S.), higher patency rate were noticed in the AT group than those in the control group in grafts on the left anterior decending and the right coronary arteries. The present study suggest that the antiplatelet treatment will play a favorable role on maintaining the graft patency.
departmental bulletin paper
新潟医学会
1994-07
application/pdf
新潟医学会雑誌
7
108
527
531
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/19251/files/108(7)_527-531.pdf
jpn